Hepatitis B vaccine developed in Cuba |
By Xinhua News Agency, Tempo, June 24, 2012
HAVANA
– Cuba has eliminated viral hepatitis B among the population aged under 15
thanks to a locally developed vaccine in the Caribbean country’s massive
immunization campaign, state media reported Saturday.
The
vaccine, Heberbiovac HB, was produced by the Center of Genetic Engineering and
Biotechnology in Havana, and the country has not reported any cases of the
disease among people aged under 15 for the last 23 years, Maria Fonte Reyes, an
expert in hygiene and epidemiology at the Health Ministry, told official daily
Granma.
Since 1992, every Cuban newborn is immunized against the hepatitis B
virus with the vaccine, Reyes said, adding that students, health staff and
dialysis patients deemed vulnerable to the virus were also vaccinated.
Currently,
all Cubans under 31 are immunized against infections, the expert said, noting
that compared with 1989, the number of hepatitis B cases in the country had
dropped by 99.09 percent to only 21 cases by the end of 2011. Those who were
infected are all aged 30 and above.
Hepatitis
B virus is spread through contact with human fluids such as blood and semen and
is one of the five identified viruses that causes liver inflammation and may
lead to chronic hepatic diseases, including cirrhosis and cancer.
The
biotech center, which exports the anti-hepatitis vaccine to some 40 countries,
has developed more than 10 vaccines which have contributed significantly to the
island’s public health, said Hugo Nodarse, director of the Department of Cancer
Research at the center.
Cuba’s
immunization programs have been credited with great success in recent years
with the development of a wide range of vaccines against chronic diseases such
as pneumonia, meningitis, diphtheria, pertussis and dengue.
The greatest achievement in the country’s medical biotech
development is the CimaVax-EGF vaccine for lung cancer, which is said to be the
only one of its kind in the world and has been exported to over 40 countries.
No comments:
Post a Comment